Castle Biosciences Inc. (CSTL), a molecular diagnostics company focused on dermatologic and gastrointestinal conditions, is drawing attention as it navigates a transitional period marked by modest revenue contraction, a narrowed quarterly loss, and a raised full-year outlook. With a new dermatology test entering the market and a strong cash position, the company is positioning itself for continued operational momentum into 2026.
Stock Performance
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.